Efficacy of CoQ10 as supplementation for migraine: A meta-analysis

source extracted confidence: high 2026-04-09
#adult #denmark #humans #migraine-disorders #ubiquinone

Efficacy of CoQ10 as supplementation for migraine: A meta-analysis

Zeng et al., 2019 | Acta Neurol Scand | Meta Analysis

Citation

Zeng ZhiYong, Li YunPeng, ... Di Wei. Efficacy of CoQ10 as supplementation for migraine: A meta-analysis. Acta Neurol Scand. 2019-Mar;139(3):284-293. doi:10.1111/ane.13051

Abstract

OBJECTIVES: Migraine ranks among the most frequent neurological disorders globally. Co-enzyme Q10 (CoQ10) is a nutritional agent that might play a preventative role in migraine. This meta-analysis aimed to investigate the effects of CoQ10 as a supplemental agent in migraine. SUBJECTS AND METHODS: Web of Science, PubMed, and Cochrane Library were searched for potential articles that assessed the effects of CoQ10 on migraine. Data were extracted by two independent reviewers and analyzed with Revman 5.2 software (The Nordic Cochrane Centre, Copenhagen, Denmark). RESULTS: We included five studies with 346 patients (120 pediatric and 226 adult subjects) in the meta-analysis. CoQ10 was comparable with placebo with respect to migraine attacks/month (P = 0.08) and migraine severity/day (P = 0.08). However, CoQ10 was more effective than placebo in reducing migraine days/month (P < 0.00001) and migraine duration (P = 0.009). CONCLUSION: This is the first study to demonstrate the effects of CoQ10 supplementation on migraine. The results support the use of CoQ10 as a potent therapeutic agent with respect to migraine duration and migraine days/month. Nonetheless, more studies are needed to support the conclusions.

Key Findings

We included five studies with 346 patients (120 pediatric and 226 adult subjects) in the meta-analysis. CoQ10 was comparable with placebo with respect to migraine attacks/month (P = 0.08) and migraine severity/day (P = 0.08). However, CoQ10 was more effective than placebo in reducing migraine days/month (P < 0.00001) and migraine duration (P = 0.009).

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 346
Age Range See abstract
Condition See abstract

MeSH Terms

  • Adult
  • Denmark
  • Humans
  • Migraine Disorders
  • Ubiquinone

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis
  • Vertical: coq10-migraine

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09